Northland Securities reiterated their corporate rating on shares of ValiRx Plc (LON:VAL) in a research report sent to investors on Thursday.

Separately, Beaufort Securities reissued a speculative buy rating on shares of ValiRx Plc in a research note on Thursday, August 11th.

ValiRx Plc (LON:VAL) opened at 7.40 on Thursday. The stock’s market cap is GBX 3.88 million. The company has a 50-day moving average price of GBX 7.51 and a 200 day moving average price of GBX 8.54. ValiRx Plc has a 12-month low of GBX 5.75 and a 12-month high of GBX 27.80.

About ValiRx Plc

ValiRx plc is a biopharmaceutical company. The principal activity of the Company is the development of oncology therapeutics and companion diagnostics. It focuses on the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis. It operates in two business segments: drug development and the sale of self-test drug kits.

Receive News & Ratings for ValiRx Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ValiRx Plc and related companies with's FREE daily email newsletter.